J&J: will present data in lung cancer

(CercleFinance.com) - Johnson & Johnson announced today that new data will be presented at this year's European Lung Cancer Congress (ELCC), to be held March 20-23 in Prague, Czech Republic.


Key data to be presented in four oral mini-presentations include the results of an analysis of a Phase 3 study evaluating the effect of dose interruptions of Rybrevant, as well as new data on the monthly subcutaneous administration of amivantamab (Phase 1b) and analyses to support the differentiated clinical profile of Rybrevant in the treatment of patients with EGFR-mutated non-small cell lung cancer.

' The breadth of data presented at ELCC underscores our commitment to redefining treatment outcomes for patients living with EGFR-mutated NSCLC ', said Kiran Patel, M.D., Vice President of Clinical Development, Solid Tumors, Johnson & Johnson Innovative Medicine.


Copyright (c) 2024 CercleFinance.com. All rights reserved.